The discovery of a BDNF single nucleotide polymorphism (SNP) that leads to decreased processing and activity-dependent release of BDNF, namely Val66Met, has further aided in elucidating the significance of BDNF in depression and response to ketamine. The gene discussed is BDNF; the disease is major depressive disorder.